Amneal Pharmaceuticals, Inc. – NYSE:AMRX
Founder-led company
Amneal Pharmaceuticals stock price today
$9.16
+1.33
+17.14%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market open
Closed in about 4 hours
Amneal Pharmaceuticals stock price monthly change
+8.76%
month
Amneal Pharmaceuticals stock price quarterly change
+8.76%
quarter
Amneal Pharmaceuticals stock price yearly change
+25.93%
year
Amneal Pharmaceuticals key metrics
Market Cap | 3.59B |
Enterprise value | 3.03B |
P/E | -1.69 |
EV/Sales | 1.37 |
EV/EBITDA | 11.01 |
Price/Sales | 0.09 |
Price/Book | 0.71 |
PEG ratio | N/A |
EPS | -0.55 |
Revenue | 2.49B |
EBITDA | 308.54M |
Income | -168.69M |
Revenue Q/Q | 18.23% |
Revenue Y/Y | 9.81% |
Profit margin | -5.88% |
Oper. margin | 8.54% |
Gross margin | 35.47% |
EBIT margin | 8.54% |
EBITDA margin | 12.37% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeAmneal Pharmaceuticals stock price history
Amneal Pharmaceuticals stock forecast
Amneal Pharmaceuticals financial statements
Average Price Target
$11
Potential upside: 20.08%
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 599.04M | 11.91M | 1.99% |
|---|---|---|---|
| Sep 2023 | 620.04M | 9.68M | 1.56% |
| Dec 2023 | 616.98M | -98.64M | -15.99% |
| Mar 2024 | 659.19M | -91.64M | -13.9% |
| 2024-03-01 | 0.07 | 0.14 |
|---|---|---|
| 2024-05-03 | 0.09 | 0.14 |
| Jun 2023 | 3700886000 | 3.51B | 95.06% |
|---|---|---|---|
| Sep 2023 | 3687079000 | 3.49B | 94.81% |
| Dec 2023 | 3472569000 | 3.45B | 99.42% |
| Mar 2024 | 3456397000 | 3.47B | 100.48% |
| Jun 2023 | -11.34M | -12.28M | -12.25M |
|---|---|---|---|
| Sep 2023 | 81.38M | -13.47M | -86.58M |
| Dec 2023 | 135.82M | -31.69M | -100.83M |
| Mar 2024 | -4.41M | -19.76M | -23.15M |
Amneal Pharmaceuticals alternative data
| Aug 2023 | 7,600 |
|---|---|
| Sep 2023 | 7,600 |
| Oct 2023 | 7,600 |
| Nov 2023 | 7,600 |
| Dec 2023 | 7,600 |
| Jan 2024 | 7,600 |
| Feb 2024 | 7,600 |
| Mar 2024 | 7,850 |
| Apr 2024 | 7,850 |
| Jul 2024 | 7,850 |
Amneal Pharmaceuticals other data
31.05%
-36.20%
of AMRX is owned by hedge funds
89
-65
46.86M
-54.94M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| May 2024 | 0 | 38000 |
| Aug 2024 | 0 | 162711 |
| Nov 2024 | 0 | 114380 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Option | KIELY JOHN director | Class A Common Stock | 28,506 | $4.76 | $135,689 | ||
Sale | KIELY JOHN director | Class A Common Stock | 17,058 | $8.38 | $142,946 | ||
Option | KIELY JOHN director | Stock Option | 28,506 | $4.76 | $135,689 | ||
Sale | AUTOR DEBORAH M. director | Class A Common Stock | 33,229 | $8.34 | $277,130 | ||
Sale | AUTOR DEBORAH M. director | Class A Common Stock | 6,771 | $8.41 | $56,944 | ||
Sale | DALY JASON B. officer: SVP, Chief Legal Officer | Class A Common Stock | 13,665 | $8.4 | $114,786 | ||
Sale | DALY JASON B. officer: SVP, Chief Legal Officer | Class A Common Stock | 43,657 | $8.61 | $375,887 | ||
Sale | BOYER ANDREW S officer: Executiv.. | Class A Common Stock | 40,225 | $7.85 | $315,766 | ||
Sale | BOYER ANDREW S officer: Executiv.. | Class A Common Stock | 22,486 | $7.81 | $175,616 | ||
Sale | SHAH NIKITA officer: Executiv.. | Class A Common Stock | 100,000 | $7.75 | $775,000 |
| Quarter | Transcript |
|---|---|
| Q1 2024 3 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 1 Mar 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 7 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 4 Aug 2023 | Q2 2023 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
| Mr. Andrew S. Boyer (1966) Executive Vice President & Chief Commercial Officer of Generics | $1,150,000 |
Mr. Anastasios G. Konidaris (1967) Executive Vice President & Chief Financial Officer | $856,850 |
Mr. Joseph Todisco MBA (1976) Executive Vice President & Chief Commercial Officer of Specialty | $790,120 |
| Ms. Nikita Shah (1978) Executive Vice President and Chief HR Officer & Strategic Planning Officer | $720,520 |
Mr. Chintu Patel R.Ph., R.Ph (1972) Co-Founder, Co-Chief Executive Officer & Director | $29,850 |
| Mr. Chirag K. Patel (1967) Co-Founder, Co-Chief Executive Officer, Pres & Director | $22,040 |
Amneal Pharmaceuticals: Maintaining Momentum Is Key To Success
Amneal Pharmaceuticals: By Most Measures, A Fundamentally Undervalued Company
Amneal Pharmaceuticals Could Have An Upbeat Q2
What To Expect From Viatris In 2023
Amneal Pharmaceuticals: Generics And Biosimilars Play Has Strong Upside Potential Under New / Old Management
-
What's the price of Amneal Pharmaceuticals stock today?
One share of Amneal Pharmaceuticals stock can currently be purchased for approximately $9.16.
-
When is Amneal Pharmaceuticals's next earnings date?
Unfortunately, Amneal Pharmaceuticals's (AMRX) next earnings date is currently unknown.
-
Does Amneal Pharmaceuticals pay dividends?
No, Amneal Pharmaceuticals does not pay dividends.
-
How much money does Amneal Pharmaceuticals make?
Amneal Pharmaceuticals has a market capitalization of 3.59B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 8.2% to 2.39B US dollars. Amneal Pharmaceuticals made a loss 83.99M US dollars in net income (profit) last year or $0.14 on an earnings per share basis.
-
What is Amneal Pharmaceuticals's stock symbol?
Amneal Pharmaceuticals, Inc. is traded on the NYSE under the ticker symbol "AMRX".
-
What is Amneal Pharmaceuticals's primary industry?
Company operates in the Healthcare sector and Drug Manufacturers - Specialty & Generic industry.
-
How do i buy shares of Amneal Pharmaceuticals?
Shares of Amneal Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Amneal Pharmaceuticals's key executives?
Amneal Pharmaceuticals's management team includes the following people:
- Mr. Andrew S. Boyer Executive Vice President & Chief Commercial Officer of Generics(age: 59, pay: $1,150,000)
- Mr. Anastasios G. Konidaris Executive Vice President & Chief Financial Officer(age: 58, pay: $856,850)
- Mr. Joseph Todisco MBA Executive Vice President & Chief Commercial Officer of Specialty(age: 49, pay: $790,120)
- Ms. Nikita Shah Executive Vice President and Chief HR Officer & Strategic Planning Officer(age: 47, pay: $720,520)
- Mr. Chintu Patel R.Ph., R.Ph Co-Founder, Co-Chief Executive Officer & Director(age: 53, pay: $29,850)
- Mr. Chirag K. Patel Co-Founder, Co-Chief Executive Officer, Pres & Director(age: 58, pay: $22,040)
-
Is Amneal Pharmaceuticals founder-led company?
Yes, Amneal Pharmaceuticals is a company led by its founders Mr. Chintu Patel R.Ph., R.Ph and Mr. Chirag K. Patel.
-
How many employees does Amneal Pharmaceuticals have?
As Jul 2024, Amneal Pharmaceuticals employs 7,850 workers, which is 3% more then previous quarter.
-
When Amneal Pharmaceuticals went public?
Amneal Pharmaceuticals, Inc. is publicly traded company for more then 7 years since IPO on 7 May 2018.
-
What is Amneal Pharmaceuticals's official website?
The official website for Amneal Pharmaceuticals is amneal.com.
-
Where are Amneal Pharmaceuticals's headquarters?
Amneal Pharmaceuticals is headquartered at 400 Crossing Boulevard, Bridgewater, NJ.
-
How can i contact Amneal Pharmaceuticals?
Amneal Pharmaceuticals's mailing address is 400 Crossing Boulevard, Bridgewater, NJ and company can be reached via phone at +90 89473120.
-
What is Amneal Pharmaceuticals stock forecast & price target?
Based on 2 Wall Street analysts` predicted price targets for Amneal Pharmaceuticals in the last 12 months, the avarage price target is $11. The average price target represents a 20.08% change from the last price of $9.16.
Amneal Pharmaceuticals company profile:
Amneal Pharmaceuticals, Inc.
amneal.comExchange:
NYSE
Full time employees:
7,850
Industry:
Drug Manufacturers - Specialty & Generic
Sector:
Healthcare
Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories. The Specialty segment is involved in the development, promotion, distribution, and sale of branded pharmaceutical products with focus on central nervous system disorders, endocrinology, parasitic infections, and other therapeutic areas. It also offers Emverm, a chewable tablet for the treatment of pinworm, whipworm, common roundworm, common hookworm, and American hookworm in single or mixed infections; Rytary to treat Parkinson's disease; and Unithroid for the treatment of hypothyroidism. The AvKARE segment provides pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. It is also involved in the wholesale distribution of bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names, as well as medical and surgical products; and packaging and wholesale distribution of pharmaceuticals and vitamins to its retail and institutional customers. The company sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. It operates in the United States, India, Ireland, and internationally. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.
400 Crossing Boulevard
Bridgewater, NJ 08807
Bridgewater, NJ 08807
CIK: 0001723128
ISIN: US03168L1052
CUSIP: 03168L105
